A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix

Cellular and Molecular Immunology

Volumn 8, Issue 1, 2011, Pages 59-66

  Shah, Walayat ^a,b   Yan, Xiaofei ^a   Jing, Li ^c   Zhou, Yi ^d   Chen, Hongwei ^a   Wang, Yili ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b KHYBER MEDICAL UNIVERSITY   (Pakistan)

^c NINGXIA MEDICAL UNIVERSITY   (China)

^d XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

CD4 CD8 ratio; cervical carcinoma; clinical outcome; tumor infiltrating lymphocytes

Indexed keywords

CD134 ANTIGEN; GRANZYME B; KI 67 ANTIGEN; PERFORIN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; REFERENCE VALUE; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CARCINOMA, SQUAMOUS CELL; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERVIX UTERI; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; UTERINE CERVICAL NEOPLASMS;

EID: 79952469085     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.56     Document Type: Article

References (57)

1. Umansky V, Schirrmacher V, Rocha M. New insights into tumor-host interactions in lymphoma metastasis. J Mol Med 1996; 74: 353-363. (Pubitemid 26291124)
2. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet 2009; 373: 673-683.
3. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC et al. Clinical significanceof tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009; 87: 365-371.
4. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H et al. Prognosticsignificanceof tumor-infiltratingT-lymphocytes in primaryand metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58:449-459.
5. + tumor infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108: 415-420. (Pubitemid 351174290)
6. Dunn GP, Dunn IF, Curry WT. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007; 7: 12.
7. Couzin J. Cancer. T cells a boon for colon cancer prognosis. Science 2006; 313: 1868-1869.
8. +/regulatoryT cell ratio areassociated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-18543. (Pubitemid 43011261)
9. Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H et al. Prognosticroleof CD8̄ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35: 808-816. (Pubitemid 38903073)
10. + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004; 28: 26-31.
11. + T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-594. (Pubitemid 28479193)
12. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753-756. (Pubitemid 29189679)
13. + Tcells: it mayget bywitha little help from its friends. JClin Invest 2002; 110: 1415-1417. (Pubitemid 35396912)
14. + T-cell response. Nat Rev Immunol 2004; 4: 595-602.
15. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 19: 850-854. (Pubitemid 35231542)
16. + regulatory T cells in colon cancer immune response in humans. Gut 2009; 58: 743-744.
17. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192.
18. + regulatory T cells in cutaneous T-cell lymphomas: association with disease stageandsurvival. Leukemia 2007; 21: 2512-2518. (Pubitemid 350148895)
19. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B et al. Increased regulatoryTcellscorrelatewith CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339. (Pubitemid 46890865)
20. Yu P, Fu YX. Tumor-infiltratingT lymphocytes: friends or foes? Lab Invest 2006; 86: 231-245.
21. + regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008;34: 173-179.
22. Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M et al. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamouscell carcinoma. Br J Cancer 2008; 98: 1258-1263. (Pubitemid 351481679)
23. Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K et al. Prognostic impact of tumor infiltratingFOXP3 positiveregulatoryTcells indiffuselargeB-cell lymphomaat diagnosis. Leuk Lymphoma 2008; 49: 247-256. (Pubitemid 351193916)
24. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006; 12: 3355-3360.
25. Yan W, Le Z, Hongyan W, Juxiang X, Lusheng S, Yili W. Theexvivomicroenvironments in MLTC of poorly immunogenic tumor cells facilitate polarization of CD4̄CD25̄ regulatory T cells. Cell Mol Immunol 2006; 3: 123-129.
26. Patel S, Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstet Gyneco 2009; 21: 54-59.
27. Loddenkemper C, Hoffmann C, Stanke J, Nagorsen D, Baron U, Olek S et al. Regulatory (FOXP3̄) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci 2009; 100: 1112-1117.
28. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. Prevalenceof human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
29. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsaguû X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527. (Pubitemid 36159887)
30. Shah W, Hongwei C, Jin Z, Lifang D, Jun Y, Yili W. The prevalence of human papillomavirus type 58 in Chinese patients with cervical carcinoma and its influenceonsurvival. Clin Oncol (R Coll Radiol). 2009; 21: 768-774.
31. + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with largeearly-stagecervical cancer. Cancer Res 2007; 67: 354-361. (Pubitemid 46142795)
32. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Resnick. Intratumoral CD8̄ T lymphocytesasaprognosticfactorof survival inendometrialcarcinoma. Clin Cancer Res 2004; 10: 4450-4456.
33. + T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possibleassociation with suppression of micrometastasis. Br J Cancer 2004; 91: 1711-1717. (Pubitemid 39546145)
34. + T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-3936. (Pubitemid 32720953)
35. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104: 3967-3972. (Pubitemid 47181562)
36. + T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94: 1003-1009. (Pubitemid 37521216)
37. + T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61: 5132-5136. (Pubitemid 32681545)
38. + T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterinecervix. Gynecol Oncol 2006; 102: 22-31. (Pubitemid 44183744)
39. Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ et al.Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 2003; 89: 271-280. (Pubitemid 36457876)
40. Baniyash M. TCR ζ-chain down regulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004; 4: 675-687. (Pubitemid 39223074)
41. Wang HY, He JJ, Shi QF, Lai BC, Ding HY, Zheng J et al. Clinicopathological significance of cytotoxic lymphocytes in breast cancer and draining lymph nodes. Zhonghua Bing Li Xue Za Zhi. 2009; 38: 384-388. Chinese.
42. + cells isassociated with increased riskof relapse insquamous cell cervical cancer. Br J Cancer 2007; 97: 1135-1138. (Pubitemid 47587015)
43. + T-cell subpopulations in headand neckcancers. Clin Cancer Res 2006; 12: 465-472 (Pubitemid 43166137)
44. + regulatory T cells for immunologicself-tolerance and negativecontrol of immune responses. Annu Rev Immunol 2004; 22: 531-562. (Pubitemid 38680433)
45. + regulatoryTcells. Semin Immunol 2004; 16: 89-98.
46. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivoadministration of anti-CD25 (interleukin-2 receptor) monoclonal antibody. Cancer Res 1999; 59: 3128-3133 (Pubitemid 29316012)
47. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-5218.
48. + regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA 2005; 102: 9253-9257. (Pubitemid 40923550)
49. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-832. (Pubitemid 32983017)
50. + regulatorycells augmentsthe generation of specific immune T cells in tumor-draining lymph nodes. JImmunother 2002; 25: 207-217. (Pubitemid 34533310)
51. + regulatory T cells specific for human papilloma virusantigens. Proc Natl Acad Sci USA 2007; 104: 12087-12092. (Pubitemid 47185634)
52. Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL, Huang SC. Reversed CD4/CD8 ratiosof tumor-infiltrating lymphocytes arecorrelated with the progression of human cervical carcinoma. Cancer 1999; 86: 1537-1543.
53. Chen L, Linsley PS, Hellström KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14: 483-486. (Pubitemid 23300998)
54. Cheng TY, Wu JT, Lin RH. Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells. Int Immunol 1998; 10: 1397-1406.
55. Greenberg PD. Adoptive T cells therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
56. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S. Major histocompatibility complex II1B7211 tumor cells are potent vaccines for stimulating tumor rejection on tumor-bearing mice. J Exp Med 1995; 181: 619-629.
57. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler S et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 246-253.